Allergy Immunotherapy Articles & Analysis: Older
18 news found
INT301 is a novel peanut desensitization immunotherapy formulated in a fully-functioning toothpaste conveniently administered during a patient’s daily toothbrushing routine. “Fully enrolling the OMEGA Clinical Study is a significant milestone for Intrommune as we continue to progress our innovative platform of products to help patients with food ...
Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. ...
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. ...
Murthy’s agreement to join our Leadership Team as Head of Regulatory is a testament to her commitment to helping patients with food allergies live better lives and her expertise in regulatory, clinical and quality affairs is a valuable addition to Intrommune as we progress our patient friendly treatment for peanut allergy, INT301 and our follow-on food ...
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow ...
” The Company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. ...
Angany introduces a new approach to allergy immunotherapy based on translational science and designed to overcome the limits of current desensitization approaches. ...
“With the launch of #PeanutAllergyStrong, Intrommune invites patients, parents, and everyone affected by peanut allergies to share their stories.” Intrommune’s lead product in development, INT301, utilizes the oral mucosal immunotherapy platform (OMIT) to decrease allergic immune response in patients through daily tooth brushing. ...
As of 1 July 2021, the Supervisory Board of the HAL Allergy Group has appointed Alex Huybens as Chief Executive Officer (CEO) and Member of the Board of HAL Allergy Holding B.V., as well as CEO of HALIX B.V. ...
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. ...
” About ANGANY ANGANY is an emerging, private Franco-Canadian pharmaceutical company dedicated to fighting allergy with a novel approach to immunotherapy. The company is pursuing a mission initiated in France in 2010. ...
Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, and Virometix AG, a company developing a new generation of vaccines and immunotherapeutic drugs, announced today that they have entered into a research collaboration. ...
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. ...
Hans van Schijndel has a PhD in Biochemistry and is employed by HAL Allergy since 2012. In his career at HAL Allergy he served as Principal Scientist/Head of Pre-clinical Research and was engaged in several bio-technological projects including the Therapieallergene-Verordnung (TAV) program. In his position of Chief R&D Officer he will take care of this ...
Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. He has held executive positions with Bayer Allergy Product/Hollister-Stier, Greer/Stallergenes and Antigen Laboratories, directing immunotherapy promotional campaigns targeting allergy ...
The corporation in Bilbao is leading in the sector of specific immunotherapy and allergy investigation, one of their focuses being the investigation of recombinant allergens. ...
These claims provide patent protection for the oral mucosal immunotherapy (OMIT) platform. OMIT enables regular administration of allergy immunotherapy while a user brushes their teeth. ...
It is customized and prescribed by a physician to address a wide range of allergies. With consistent use, allergy immunotherapy has been shown to significantly reduce or eliminate the body's allergic responses to pollen, animal dander, dust, insects and other allergens. ...